Cargando…

A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis

AIM: Covert hepatic encephalopathy (CHE) adversely affects clinical outcomes in patients with liver cirrhosis, although its diagnosis is difficult. This study aimed to establish a simple CHE screening model based on blood-related biochemical parameters. METHODS: This retrospective study enrolled 439...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miwa, Takao, Hanai, Tatsunori, Nishimura, Kayoko, Maeda, Toshihide, Tajirika, Satoko, Imai, Kenji, Suetsugu, Atsushi, Takai, Koji, Yamamoto, Mayumi, Shimizu, Masahito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710772/ https://www.ncbi.nlm.nih.gov/pubmed/36449492 http://dx.doi.org/10.1371/journal.pone.0277829

Ejemplares similares

Association between Body Composition and the Risk of Portopulmonary Hypertension Assessed by Computed Tomography in Patients with Liver Cirrhosis
por: Miwa, Takao, et al.
Publicado: (2023)

Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2023)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Usefulness of the Trabecular Bone Score in Assessing the Risk of Vertebral Fractures in Patients with Cirrhosis
por: Ogiso, Yui, et al.
Publicado: (2022)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2021)

Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers
por: Imai, Kenji, et al.
Publicado: (2021)

Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

FIB‑4 index and NAFLD fibrosis score are useful indicators for screening high‑risk groups of non‑viral hepatocellular carcinoma
por: Imai, Kenji, et al.
Publicado: (2023)

Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates
por: Imai, Kenji, et al.
Publicado: (2023)

Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2018)

Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2019)

Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020)

Usefulness of health checkup for screening metabolic dysfunction-associated fatty liver disease and alcohol-related liver disease in Japanese male young adults
por: Tajirika, Satoko, et al.
Publicado: (2023)

Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study
por: Miwa, Takao, et al.
Publicado: (2022)

Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report
por: Miwa, Takao, et al.
Publicado: (2021)

Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2019)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume
por: Imai, Kenji, et al.
Publicado: (2017)

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Unome, Shinji, et al.
Publicado: (2022)

Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review
por: Sakai, Hiroyasu, et al.
Publicado: (2020)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2015)

Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease
por: Miwa, Takao, et al.
Publicado: (2022)

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies
por: Labenz, Christian, et al.
Publicado: (2020)

Altered cognitive control network is related to psychometric and biochemical profiles in covert hepatic encephalopathy
por: Tsai, Chia-Fen, et al.
Publicado: (2019)

Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis
por: Gairing, Simon Johannes, et al.
Publicado: (2023)

Adventures in Developing an App for Covert Hepatic Encephalopathy
por: Bajaj, Jasmohan S
Publicado: (2017)

Urinary metabolic profiling by (1)H NMR spectroscopy in patients with cirrhosis may discriminate overt but not covert hepatic encephalopathy
por: McPhail, Mark J. W., et al.
Publicado: (2016)

Prevalence of Covert Hepatic Encephalopathy in A Tertiary Care Centre
por: Pathak, Rahul, et al.
Publicado: (2020)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Spur cell anemia related to alcoholic liver cirrhosis managed without liver transplantation: a case report and literature review
por: Miwa, Takao, et al.
Publicado: (2020)

Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2014)

Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients
por: Wang, An-Jiang, et al.
Publicado: (2017)

Evaluating sleep in covert encephalopathy with wearable technology: results from the WATCHES study
por: Buckholz, Adam, et al.
Publicado: (2023)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Covert vascular brain injury in chronic kidney disease
por: Miwa, Kaori, et al.
Publicado: (2022)

Impact of Hepatitis C Virus Infection on Cognitive Function in Patients With Covert Hepatic Encephalopathy
por: Hashemi, Farnaz, et al.
Publicado: (2015)

Radiomics‐based classification models for HBV‐related cirrhotic patients with covert hepatic encephalopathy
por: Luo, Sha, et al.
Publicado: (2020)

Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis
por: Demirciler, Erkut, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4vasr78ahivrfo1jhu6oocug4r